Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June
Executive Summary
Wyeth-Ayerst will file a low-dose PremPro sNDA for osteoporosis by the end of June, North American President Joseph Mahady said during American Home Products' May 16 analyst meeting in New York City.
You may also be interested in...
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Wyeth's approval of lower-dose Prempro gives the company a positive marketing message to counter the safety concerns raised by the Women's Health Initiative hormone replacement therapy study findings
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Wyeth's approval of lower-dose Prempro gives the company a positive marketing message to counter the safety concerns raised by the Women's Health Initiative hormone replacement therapy study findings
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Wyeth-Ayerst believes it can continue to grow the Premarin franchise in 2002 despite another delay in the projected launch date for a low-dose formulation of the conjugated estrogen/progestin combo Prempro.